Myopathy, Lactic acidosis, and Sideroblastic Anemia 2
MLASA2

Contact us
 
Return to database


We were unfortunately unable to download the information for this disease from OMIM.



Prevalence of clinical parameters (%)







Add new symptom/sign to this disease

Select symptom from list or write it in the box
Pubmed id number as a reference Organ system affected
Number of patients in the reference Percent affected patients (Between 0 and 1, eg. 0.1 = 10%)
Please provide your name and contact information as a reference
Name Institute Phone number Email address


List of symptoms



Symptom/sign Organ system Percent affected Pubmed id Added on(yyyy-mm-dd) Edit/add reference
Anemia circulatory 100 % 20598274 2011-10-19
Lactate accumulation circulatory 100 % 20598274 2011-10-19
Myopathy skeletal 100 % 20598274 2011-10-19
Exercise intolerance skeletal 100 % 20598274 2011-10-19
Muscle weakness skeletal 100 % 20598274 2011-10-19
Pallor circulatory 67 % 20598274 2011-10-19
Dysphagia digestive 67 % 20598274 2011-10-19
Short stature skeletal 67 % 20598274 2011-10-19
Weight loss multi 67 % 20598274 2011-10-19
Cardiomyopathy circulatory 33 % 20598274 2011-10-19
Lethargy circulatory 33 % 20598274 2011-10-19
Failure to thrive multi 33 % 20598274 2011-10-19
Developmental delay nervous 33 % 20598274 2011-10-19



List of references:


Mutation of the mitochondrial tyrosyl-tRNA synthetase gene, YARS2, causes myopathy, lactic acidosis, and sideroblastic anemia--MLASA syndrome.
Lisa G Riley, Sandra Cooper, Peter Hickey, Joëlle Rudinger-Thirion, Matthew McKenzie, Alison Compton, Sze Chern Lim, David Thorburn, Michael T Ryan, Richard Giegé, Melanie Bahlo, John Christodoulou,

Mitochondrial respiratory chain disorders are a heterogeneous group of disorders in which the underlying genetic defect is often unknown. We have identified a pathogenic mutation (c.156C>G [p.F52L]) in YARS2, located at chromosome 12p11.21, by using genome-wide SNP-based homozygosity analysis of a family with affected members displaying myopathy, lactic acidosis, and sideroblastic anemia (MLASA). We subsequently identified the same mutation in another unrelated MLASA patient. The YARS2 gene product, mitochondrial tyrosyl-tRNA synthetase (YARS2), was present at lower levels in skeletal muscle whereas fibroblasts were relatively normal. Complex I, III, and IV were dysfunctional as indicated by enzyme analysis, immunoblotting, and immunohistochemistry. A mitochondrial protein-synthesis assay showed reduced levels of respiratory chain subunits in myotubes generated from patient cell lines. A tRNA aminoacylation assay revealed that mutant YARS2 was still active; however, enzyme kinetics were abnormal compared to the wild-type protein. We propose that the reduced aminoacylation activity of mutant YARS2 enzyme leads to decreased mitochondrial protein synthesis, resulting in mitochondrial respiratory chain dysfunction. MLASA has previously been associated with PUS1 mutations; hence, the YARS2 mutation reported here is an alternative cause of MLASA.

American journal of human genetics - Jul 2010